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I
n the development of percutaneous intervention, Dotter
first used unfractionated heparin (UFH) alone when
performing peripheral angioplasty.1 In the 1970s
Gruentzig added 1 g of aspirin (ASA) for three days in
coronary angioplasty, which was started the day before the
procedure.2 Over the ensuing years empiric attempts were
made to improve patient outcomes using dextran and
dipyridamole but without success. More recently, along with
ASA and UFH, direct thrombin inhibitors, low molecular
weight heparin (LMWH), warfarin, fibrinolytics, thienopyr-
idines, and platelet glycoprotein (Gp) IIb/IIIa antagonists
have all been studied in efforts to reduce the thrombotic
complications associated with a percutaneous coronary
intervention (PCI).
Of the multiple combinations of antithrombotic agents that
have been tried and tested, only several have been unequi-
vocally proven to be beneficial in placebo controlled trials. A
number of others continue to be studied or have persisted
empirically. ASA, thienopyridines, UFH, LMWH, direct throm-
bin inhibitors, and Gp IIb/IIIa antagonists are currently the
most commonly utilised antithrombotic agents. As a result of
improvements in the antithrombotic regimen, in conjunction
with improvements in equipment and technique, the incidence
of periprocedural major adverse cardiac events (MACE) and
major bleeding have continued to improve.
ANTIPLATELET THERAPY
Aspirin
Aspirin (acetylsalicylic acid, ASA) has been available for over
a century yet its cardiac and vascular benefits have only been
realised in the last 50 years. The benefit of ASA as antiplatelet
treatment in PCI is frequently under-appreciated, but has
been well established in short and long term placebo
controlled studies. Schwartz showed that the addition of
aspirin to heparin in PCI was associated with a 77% relative
risk reduction in MACE (p = 0.013).3 Similarly, White
showed that aspirin when combined with heparin was
associated with a 75% reduction in MACE (p , 0.001)
compared to heparin alone.4 A longer duration of aspirin
treatment after PCI is supported by the M-Heart II study. In
this case, six months of ASA treatment was associated with
less reinfarction when compared with placebo (1.2% v 5.7%).5
Lifelong ASA treatment in PCI patients is further recom-
mended on the basis of extrapolating from primary and
secondary prevention data.
Ticlopidine
The early experience with ticlopidine alone in PCI patients is
limited, but when started four days before the intervention
showed similar protection from periprocedural events as did
ASA.4 In coronary stenting, data from multiple randomised
trials have convincingly proven the benefit of dual antiplate-
let treatment with the combination of ASA and ticlopidine
than either ASA alone or in combination with warfarin.6
However, ticlopidine has been noted to cause trans-
ient neutropenia in 0.4–2% of patients and thrombotic
thrombocytopenic purpura in approximately 1 in every
1500–4000 patients.7 Consequently, clopidogrel has essen-
tially replaced ticlopidine in patients undergoing a PCI.
Clopidogrel
Clopidogrel has been compared to ticlopidine in only one
blinded, controlled trial. In the CLASSICS trial, which was
powered based on a primary safety end point, clopidogrel was
better tolerated in combination with ASA compared to
ticlopidine, with similar clinical efficacy.8 The combined
results of two prospective, non-blinded but randomised trials
and multiple registries, which in total included nearly 14 000
patients, also confirmed the better tolerability of clopidogrel
and at least similar efficacy to ticlopidine.9
Early observational studies suggested that pretreatment
with ticlopidine or clopidogrel was associated with a lower
rate of periprocedural thrombotic events.10 Consistent with
these early findings, the PCI-CURE subset analysis of the
CURE trial also found a similar benefit of pretreatment. In
this analysis 2658 patients underwent PCI at a median of 10
days after randomisation, having received ASA 75–325 mg
and clopidogrel 300 mg followed by 75 mg daily, or matching
placebo starting at the time of randomisation.11 Following
PCI, each patient received open label clopidogrel or ticlopi-
dine for ,4 weeks after the procedure followed by a mean
total duration of nine months of the previously assigned
study medication. Pretreatment with clopidogrel was asso-
ciated with a 30% relative risk reduction (44% if no open
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labelled thienopyridine treatment) in 30 day cardiovascular
(CV) death, MI, or urgent target vessel revascularisation
(TVR) (6.4% v 4.5%; 95% CI 0.52 to 0.89; p = 0.005).
In the CREDO trial, the only prospective, blinded,
randomised trial of clopidogrel treatment before PCI, a
300 mg clopidogrel loading dose started 3–24 hours before
PCI was associated with only a non-significant ,19% relative
risk reduction in 28 day MACE compared with the control
arm that received no pretreatment and no loading dose.12
Based on the findings of a prespecified subgroup analysis, the
investigators found a strong relation between the duration of
pretreatment and the clinical benefit. Pretreatment with
300 mg of clopidogrel at least 6–24 hours before PCI was
associated with a 38.6% relative risk reduction in MACE at 28
days (5.8% v 9.4%, p = 0.051). Subsequent analysis has
suggested that in order to achieve the benefit of a 300 mg
clopidogrel loading dose, pretreatment for at least 15 hours is
required. In fact an inverse relation between the duration of
pretreatment and risk of death, MI, or urgent TVR was found,
only in patients randomised to clopidogrel. This benefit was
not significant until over 15 hours of pretreatment (odds
ratio 0.73, p = 0.024), and the magnitude of this benefit
increased with an increasing duration of pretreatment.13
The optimal dose of clopidogrel needed to minimise the
duration of pretreatment is not yet well established, but is
likely to be . 300 mg. One study has found a much faster
onset, but similar final levels of ADP induced platelet
inhibition with 600 mg pre-loading of clopidogrel at least
two hours before PCI, compared with 2 6 500 mg loading
dose of ticlopidine, or to clopidogrel 300 mg.14 The clinical
value of this higher dose loading regimen was studied in the
ISAR-REACT trial involving 2159 low to moderate risk
patients undergoing a non-urgent PCI.15 All patients were
pretreated with 600 mg of clopidogrel at least two hours
before PCI and then randomised to either abciximab or
matching placebo. Importantly, the addition of abciximab
following the clopidogrel load did not lead to any incremental
benefit in thrombotic events. Unlike the CREDO findings,
subsequent analysis of ISAR-REACT suggested no time
dependence of the clinical benefit of the 600 mg clopidogrel
loading dose (Berger PB, presented at the 2003 Scientific
Sessions of the American Heart Association), suggesting that
pretreatment should be given as a 600 mg dose if time delay
to anticipated PCI is less than 15–24 hours.
The optimal duration of clopidogrel treatment following a
PCI is unknown, although all available data suggest that
longer durations lead to greater benefit. Arbitrarily, 2–4
weeks has been routinely utilised following treatment with a
bare metal stent to treat the time period of greatest risk for
stent thrombosis. However, over the long term PCI patients
remain at heightened risk for future thrombotic events
unrelated to the treated lesion, and, therefore, ongoing
treatment with clopidogrel in addition to ASA may be of
benefit in decreasing these events. The CURE trial and its
substudy, PCI-CURE, have both shown that combination
treatment with ASA and clopidogrel for a mean of nine
months is associated with a widening reduction in the
occurrence of death, MI, and stroke.11 In CREDO, continuing
clopidogrel on top of ASA for 12 months also demonstrated a
widening benefit over time, with a ,2% absolute risk
reduction between 29 days and one year, but a trend towards
an increase in major bleeding.12 With drug eluting stents, at
least 3–6 months of clopidogrel has been studied and should
be utilised.
Glycoprotein IIb/IIIa antagonists
Gp IIb/IIIa antagonists in combination with ASA have
consistently been shown to reduce MACE after PCI compared
with placebo (fig 1). In pooled analysis of PCI trials
comparing Gp IIb/IIIa antagonists versus placebo, there was
a 35% relative risk reduction (RR) in the combined end point
of death and MI at 30 days with Gp IIb/IIIa antagonists (7.9%
v 11.6%, RR 0.65, 95% CI 0.59 to 0.72).16 Although lesion
characteristics do not seem to be predictive of the benefit of a
Gp IIb/IIIa antagonist,17 several serum markers of thrombosis
or platelet activation (for example, troponin, plasma CD40
ligand) are able to identify subgroups of patients who do and
do not benefit from the addition of a Gp IIb/IIIa antagonist.18
Diabetic patients also appear to achieve benefits significantly
greater than non-diabetics, especially those being treated
with a PCI in the setting of an acute coronary syndrome
(ACS).19 In contrast, in patients undergoing saphenous vein
graft PCI, there is little evidence to show that these patients
are protected from adverse thrombotic events with the use of
a Gp IIb/IIIa antagonist.20
The TARGET trial is the only head-to-head study that
compared Gp IIb/IIIa antagonists, and while it was designed
as a non-inferiority trial, it actually demonstrated a sig-
nificant 26% higher incidence of 30 day death, MI, and
urgent TVR in those patients treated with tirofiban (6.0% v
7.6%, p = 0.038).21 It has been speculated that the dosing of
tirofiban led to the inferior results. This is currently being
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Figure 1 The effect of glycoprotein IIb/IIIa antagonists on 30 day mortality and myocardial infarction in percutaneous coronary intervention.




UFH was originally empirically used for the prevention of
thrombotic events in patients undergoing PCI and today it
remains the most widely used intravenous anticoagulant in
modern PCI practice. There are several theoretical short-
comings with its use: wide variability in anticoagulant effect;
its limited and uncertain bioavailability; the potential to
cause platelet activation, and its inability to inhibit clot
bound thrombin.22
Low molecular weight heparin
Several small non-randomised trials have been performed
using LMWH in PCI patients. The series of NICE trials
provided observational data on the use of enoxaparin in PCI
with or without Gp IIb/IIIa antagonists. In NICE 3, 628
patients with an ACS were treated with enoxaparin and early
Gp IIb/IIIa antagonist, with 283 patients eventually under-
going a PCI. In those patients treated with a subcutaneous
dose of enoxaparin within eight hours of PCI no additional
anticoagulation was given, while in patients who received
enoxaparin over eight hours, an additional 0.3 mg/kg of
intravenous enoxaparin was given at the time of PCI.
Compared with historical controls, efficacy and safety
outcomes were favourable with enoxaparin.23 Preliminary
data suggest that the use of low dose intravenous enoxaparin
as the primary anticoagulant in the setting of an elective PCI
is both safe and efficacious.24 The ongoing prospective,
randomised STEEPLE trial will address the safety and
efficacy of two doses of enoxaparin (0.5 mg/kg and
0.75 mg/kg) compared with UFH, with or without a Gp IIb/
IIIa antagonist, in ,2700 non-urgent PCI patients.
Direct thrombin inhibitors
Although there are several direct thrombin inhibitors available,
only bivalirudin has been extensively studied in the setting of
modern PCI. In the REPLACE 2 trial, bivalirudin was found to
be as efficacious as UFH plus a Gp IIb/IIIa antagonist but with a
significantly lower bleeding risk.25 REPLACE 2 was a non-
inferiority trial of 6012 urgent or elective PCI patients whowere
randomised to UFH plus a Gp IIb/IIIa antagonist or bivalirudin
with bailout Gp IIb/IIIa use only. The primary, quadruple end
point (death, MI, urgent TVR, or major bleeding) at 30 days
was equivalent in both arms (9.2% v 10%, p = NS). The role of
bivalirudin, with and without a Gp IIb/IIIa antagonist, in ACS
patients likely to undergo a PCI, is currently being studied in
the ,13 800 patient ACUITY trial.
Future directions
Antiplatelet treatment is constantly evolving. A new intra-
venous P2Y12 antagonist (cangrelor) can induce greater
platelet inhibition than clopidogrel and it is reversible.
Clinical trials are underway and results are eagerly
awaited.26 27 An alternative oral thienopyridine agent (CS-
747) is being evaluated in the JUMBO-TIMI 26 trial, a phase
II PCI study, and these results should be available soon. A
reversible, oral P2Y12 antagonist, AZD-6140, is also just
starting phase III studies.
Novel antithrombotic treatments include factor Xa antago-
nists (fondaparanox), and the oral direct thrombin inhibitor
ximelagatran. Fondaparanox is currently being evaluated in
PCI patients in the OASIS 5 trial.
CONCLUSION
Antiplatelet and anticoagulant treatments are essential in the
management of PCI patients. Aspirin should be given to all
patients and likely maintained lifelong. Currently, all PCI
patients should be pretreated with clopidogrel before PCI
whenever possible. Ideally, 300 mg at least 15–24 hours or
600 mg two hours before PCI is preferable. In the long term
one year of clopidogrel 75 mg daily provides ongoing clinical
benefit in terms of event reduction when combined with
aspirin. Glycoprotein IIb/IIIa antagonists reduce adverse
events in PCI patients, especially those with high risk
features such as an elevated troponin value. UFH remains
the most widely used antithrombotic treatment, although
never formally studied, and alternative agents such as
bivalirudin, which has already been shown to be more
effective, and enoxaparin, currently being studied, may
change this. Finally, multiple new antithrombotic agents
continue to undergo testing in clinical trials and it is likely
that what is currently standard of care will evolve notably
over the next several years.
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